NASDAQ: COEPCoeptis Therapeutics Holdings Inc Stock
$0.35-0.02 (-5.41%)
Updated Apr 18, 2024
COEP Price
$0.35
Fair Value Price
N/A
Market Cap
$12.67M
52 Week Low
$0.29
52 Week High
$2.19
P/E
-0.42x
P/B
2.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.87
Operating Cash Flow
-$7M
Beta
0.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how COEP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COEP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
COEP is good value based on its book value relative to its share price (2.94x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
COEP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more COEP due diligence checks available for Premium users.
Be the first to know about important COEP news, forecast changes, insider trades & much more!
COEP News
Valuation
COEP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.42x
Industry
15.68x
Market
41.33x
COEP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.94x
Industry
5.76x
COEP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COEP's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
COEP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.1M
Liabilities
$3.8M
Debt to equity
0.87
COEP's short-term assets ($5.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COEP's short-term assets ($5.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COEP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
COEP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
$0.0
Financing
$1.8M
COEP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COEP vs Biotech Stocks
Coeptis Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.